Septic Shock
Conditions
Keywords
septic shock, simvastatin
Brief summary
The beneficial effect of statins to prevent cardiovascular events in patients at risk is well established. Recent trials demonstrated that statins can exert a number of vascular actions independent of lipid lowering. Short-term simvastatin therapy recently has been reported to reduce mortality in 2 different animal models of sepsis. Pleiner and coworkers could demonstrate potent vasoprotective properties of simvastatin during Escherichia coli endotoxin induced endotoxemia in healthy volunteers. In a population-based cohort analysis it was demonstrated that administration of statins was associated with a reduced risk of subsequent sepsis. Thus, simvastatin treatment may offer a new therapeutic strategy for clinical conditions associated with inflammation like severe sepsis and septic shock. The aim of the present study is to test the hypothesis that short term treatment with simvastatin may mitigate the detrimental vascular effects of acute inflammation in patients admitted to the intensive care unit requiring treatment for septic shock.
Interventions
DRUGSimvastatin
Sponsors
Medical University of Vienna
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Septic Shock for less than 48 hours
Exclusion criteria
* Pregnancy * Unable to receive enteral medications * Expected survival of less than 72 hours * Treatment in the previous 3 weeks with simvastatin or other HMG-CoA reductase inhibitors * History of hypersensitivity to the trial drug or to drugs with a similar chemical structure * History of known or suspected porphyria * High risk of rhabdomyolysis (multiple trauma, crush injuries, extensive burns, baseline creatinine kinase (CK) ≥ten-times upper limit of normal * Hemorrhagic shock
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to shock reversal as defined by cessation of vasopressor support > 1 hour | — |
Countries
Austria
Contacts
Primary ContactPeter Schenk, MD
Outcome results
None listed